DelveInsight's "Chronic Pruritus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Pruritus, historical and forecasted epidemiology as well as the Chronic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Highlights Chronic Pruritus Market
-
Key Companies working in the Chronic Pruritus market are Vyne Therapeutics, Haisco Pharmaceutical, Sanofi, Trevi Therapeutics, Sanofi and many others.
-
Key Therapies in Chronic Pruritus are Dupilumab, Pregabalin, Nalbuphine HCl ER, and many others.
Chronic Pruritus Overview
Chronic pruritus, commonly known as chronic itching, is a persistent and distressing skin condition characterized by an uncontrollable urge to scratch. It can result from various underlying causes, such as skin disorders (eczema, psoriasis), systemic diseases (liver or kidney dysfunction), neurological conditions (nerve damage), or medication side effects. Chronic pruritus can significantly impact a person's quality of life, leading to sleep disturbances, social isolation, and emotional distress. Diagnosis typically involves a thorough medical history, physical examination, and sometimes, laboratory tests or skin biopsies to identify the root cause. Treatment options aim to address the underlying condition, relieve itching, and prevent skin damage due to scratching. These may include topical creams, antihistamines, moisturizers, or systemic therapies like immunosuppressants. Management often requires a multidisciplinary approach involving dermatologists, allergists, and other specialists to provide effective relief and improve the patient's overall well-being.
Chronic Pruritus Epidemiology Insights
-
Population-based studies, such as the Lambeth study (14), have shown a prevalence of prurigo and allied conditions of 8.2%, while a Norwegian study (15, 16) reported a prevalence of acute pruritus within the last week of 8.4% in an urban population aged 30–76 years. A population-based study in France estimated the prevalence of pruritus at 12.4% during a 2-year period however, no description was provided of how chronic pruritus was defined. Neither of these population-based studies assessed chronic pruritus (point, 12-month, lifetime prevalence) or used well-defined criteria for the assessment of chronic pruritus. To our knowledge there is only one study (n = 11,732) measuring chronic itch in a non-diseased population.
-
The point prevalence of chronic pruritus was 13.5% (95% confidence interval (95% CI) 12.2–14.9%), 12-month prevalence 16.4% (15.0–17.9%), and lifetime prevalence 22.0% (20.4–23.7%). Multivariate analyses found only ethnic origin independently associated with chronic pruritus. The impact of chronic pruritus on quality of life and emotional well-being appears to depend on severity rather than on the presence of the symptom alone.
Click here to learn more about the Chronic Pruritus Market Landscape
The Report Covers the Chronic Pruritus Epidemiology Segmented by:
-
Chronic Pruritus prevalent cases
-
Chronic Pruritus incident cases
-
Chronic Pruritus treatment cases
-
Chronic Pruritus diagnosed cases
Chronic Pruritus Market Outlook
The Chronic Pruritus market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Pruritus market trends by analyzing the impact of current Chronic Pruritus therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Chronic Pruritus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Pruritus market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chronic Pruritus market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Chronic Pruritus Market
-
Vyne Therapeutics
-
Haisco Pharmaceutical
-
Trevi Therapeutics
-
Sanofi
And many others.
Chronic Pruritus Therapies Covered and Analyzed in the Report
-
Dupilumab
-
Pregabalin
-
Nalbuphine HCl ER
And many others.
Learn more about the Key Companies and Emerging Therapies in the Chronic Pruritus Market
Table of Contents
-
Key Insights
-
Chronic Pruritus Introduction
-
Executive Summary of Chronic Pruritus
-
Disease Background and Overview
-
Epidemiology and patient population
-
Chronic Pruritus Emerging Therapies
-
Chronic Pruritus Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Chronic Pruritus Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
